Page 93 - JCTR-11-3

Journal of Clinical and
Translational Research Remdesivir outcomes in hospitalized COVID-19

doi: 10.1002/JMV.27768 10 days in patients with severe Covid-19. N Engl J Med.
2020;383:1827-1837.
16. Chen N, Zhou M, Dong X, et al. Epidemiological and
clinical characteristics of 99 cases of 2019 novel coronavirus doi: 10.1056/NEJMOA2015301
pneumonia in Wuhan, China: A descriptive study. Lancet. 26. Pasquini Z, Montalti R, Temperoni C, et al. Effectiveness of
2020;395:507-513. remdesivir in patients with COVID-19 under mechanical
doi: 10.1016/S0140-6736(20)30211-7 ventilation in an Italian ICU. J Antimicrob Chemother.
2020;75:3359-3365.
17. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes
of critically ill patients with SARS-CoV-2 pneumonia doi: 10.1093/JAC/DKAA321
in Wuhan, China: A single-centered, retrospective, 27. Manudhane G, Kumbhar M, Yadav A, et al. To study role
observational study. Lancet Respir Med. 2020;8:475-481. of remdesivir in COVID 19 patients at a tertiary referral
doi: 10.1016/S2213-2600(20)30079-5 hospital in Mumbai, India. J Assoc Physicians India.
2021;69:30-32.
18. Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate
remdesivir treatment of severe Covid-19 pneumonia in 28. Gao YD, Ding M, Dong X, et al. Risk factors for severe
intensive care unit (ICU) and Non-ICU patients: Clinical and critically ill COVID-19 patients: A review. Allergy.
outcome and differences in post-treatment hospitalisation 2021;76:428-455.
status. Pharmacol Res. 2020;158:104899. doi: 10.1111/ALL.14657
doi: 10.1016/J.PHRS.2020.104899 29. Ayodele O, Ren K, Zhao J, et al. Real-world treatment

19. Hasanoğlu I, Güner R, Çelik I, et al. Remdesivir treatment patterns and clinical outcomes for inpatients with
for patients with moderate to severe COVID-19. Turk J Med COVID-19 in the US from September 2020 to February
Sci. 2022;52:880-887. 2021. PLoS One. 2021;16(12):e0261707.
doi: 10.55730/1300-0144.5387 doi: 10.1371/JOURNAL.PONE.0261707
20. Tsuzuki S, Hayakawa K, Uemura Y, et al. Effectiveness 30. Vititoe SE, Govil P, Baglivo A, et al. A descriptive
of remdesivir in hospitalized nonsevere patients with cohort study of drug utilization patterns among patients
COVID-19 in Japan: A large observational study using the hospitalized with coronavirus disease 2019 in the United
COVID-19 registry Japan. Int J Infect Dis. 2022;118:119-125. States, January 2021-February 2022. Open Forum Infect Dis.
2023;10(7):ofad339.
doi: 10.1016/J.IJID.2022.02.039
doi: 10.1093/OFID/OFAD339
21. Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in
the transmission and control of COVID-19 epidemics. Nat 31. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus
Med. 2020;26:1205-1211. remdesivir for hospitalized adults with Covid-19. N Engl J
Med. 2021;384:795-807.
doi: 10.1038/S41591-020-0962-9
doi: 10.1056/NEJMOA2031994
22. Amgalan A, Malinowski AK, Othman M. COVID-19
and sex-/gender-specific differences: Understanding the 32. Karolyi M, Kaltenegger L, Pawelka E, et al. Early
discrimination. Semin Thromb Hemost. 2021;47:341-347. administration of remdesivir may reduce mortality in
hospitalized COVID-19 patients : A propensity score
doi: 10.1055/S-0040-1715455 matched analysis. Wien Klin Wochenschr. 2022;134:
23. Acharya TA, Joshi KJ, Patel DD, Shah SN, Mehta DS. 883-891.
Study of clinical outcome and healthcare modalities of doi: 10.1007/S00508-022-02098-9
COVID-19 patients treated with remdesivir at a tertiary care
teaching hospital. Cureus. 2022;14(1):e21535. 33. Tejada D, Juanbeltz R, Rivero M, et al. Clinical course of
patients with severe COVID-19 pneumonia treated with
doi: 10.7759/CUREUS.21535 remdesivir: A real-life study. PLoS One. 2022;17(4):e0267283.
24. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting doi: 10.1371/JOURNAL.PONE.0267283
characteristics, comorbidities, and outcomes among 5700 34. Sellers J, Chang J, Jones J, Hintze TD. Patients with moderate
Patients hospitalized with COVID-19 in the New York City to severe COVID-19 outcomes on remdesivir according
Area. JAMA. 2020;323:2052-2059.
to baseline 4C mortality score. Pulm Pharmacol Ther.
doi: 10.1001/jama.2020.6775 2023;78:102188.
25. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or doi: 10.1016/J.PUPT.2022.102188

Volume 11 Issue 3 (2025) 87 doi: 10.36922/jctr.24.00027